GSK : presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains

Preliminary results from phase III trial show all primary endpoints met, demonstrating statistical non-inferiority compared to Bexsero and Menveo , in individuals 10-25 years old with... | May 12, 2023

Related Keywords

Lisbon ,Lisboa ,Portugal ,United States ,Australia ,Canada ,Czech Republic ,Melbourne ,Victoria ,Estonia ,Turkey ,Finland ,Bexsero Men ,Terry Nolan ,Bing Wang ,Tony Wood ,Menveo Men ,Immunisation Research Group ,University Of Melbourne ,Peter Doherty Institute For Infection ,National Immunization ,National Vaccination Coverage Among Adolescents ,Murdoch Children Research Institute ,Representative Panel ,Annual Meeting ,European Society ,Paediatric Infectious Diseases ,Chief Scientific Officer ,Peter Doherty Institute ,Murdoch Children ,Research Institute ,Biologics License Application ,Accelerated Approval ,Annual Report ,Disease Causes ,How It Spreads ,Based Outbreaks ,Meningococcal Disease Caused ,Infectious Diseases ,Vaccination Coverage Among Adolescents Aged ,Immunization Survey Teen ,Mortal Wkly Rep ,Gsk Plc Stock Exchange ,News ,Information ,Press Release ,Reliminary ,Results ,Rom ,Hase ,Wii ,Trial ,Show ,Wall ,Primary ,Endpoints ,Emonstrating ,Tatistical ,Ompared ,O ,Bexsero ,End ,Cenveo ,N ,Individuals ,Tears ,Ld Gsk Gb00bn7swp63 ,